Search
Search
Upstream (USP) work often slows when titers, clone stability, or early optimization steps fall short of expectations. Build a stronger start by combining stable cell line development, informed media and feed selection, and early benchtop bioreactor evaluation. Together, these activities help reduce variability, improve consistency, and create a more scalable foundation for monoclonal antibody (mAb) bioprocessing.
Upstream development can slow when teams must balance cell line selection, nutrient optimization, and early bioreactor studies under tight timelines. Help unify these steps with connected upstream tools from Gibco Freedom cell line development kits and Chinese hamster ovary (CHO) screening panels to the Gibco Efficient-Pro Media and Feed System and scale-ready bioreactors. This integrated approach helps improve productivity, reduce variability, and support smooth transitions from screening to process optimization.
Early benchtop studies often determine whether upstream gains can translate to larger volumes, yet teams may face gaps in control, monitoring, and scalability. Facilitate this bridge between optimization and scale-up by using benchtop bioreactors equipped with modular hardware, integrated sensors, and flexible control platforms. These systems support precise adjustment of parameters, such as pH, temperature, agitation, and gas transfer, enabling selected clones to perform reliably as processes advance toward pilot and manufacturing stages.
Upstream variability can introduce impurities or contamination risks that affect mAb downstream (DSP) efficiency and overall batch success. Apply analytical and impurity testing solutions to monitor culture health, verify purity, and support regulatory-aligned process verification. Mycoplasma detection solutions, including Applied Biosystems MycoSEQ platforms, offer rapid, sensitive screening to help teams identify issues early and maintain consistent product quality throughout development.
Select a productive clone using CHO Freedom cell line development kits designed to produce stable mAb-producing clones. Work with FAS for clone selection and effective cell culture media and feed screening. This combined approach was developed to identify top clones, address variability, and accelerate early upstream development.
Maximizing titers begins with balancing nutrient supply throughout the culture process. The Efficient-Pro System offers matched formulations that support consistent performance across CHO cell lines. Media and feed panel screenings further help identify optimal combinations through data-driven comparisons. Using these insights, teams can refine culture conditions to improve productivity and reduce run-to-run variability in mAb production.
Offline analytics help reduce upstream risk by enabling early detection and consistent monitoring. PCR-based contamination assays, such as mycoplasma testing, offer rapid identification of contamination that could compromise clone stability. Pairing these methods with routine titer measurements supports selection and banking of high-producing, mycoplasma-free clones. Together, these strategies offer timely insights that can strengthen decision-making during upstream development.
Designing an effective seed train is important for translating early gains to larger volumes. Evaluate clone behavior across small-scale bioreactors and consider N-1 strategies to support consistent growth. Solutions, such as the DynaDrive System, flexible bioprocessing controllers, and automation platforms, help teams standardize mixing, gas transfer, and control parameters, allowing for more predictable scale-up and smoother transition to pilot and manufacturing stages.
Upstream decisions directly influence downstream capacity and efficiency. Higher titers and cell densities can increase impurity loads, influencing downstream strategies that can adapt to increasing mAb quantities and impurities. Screening high-capacity affinity chromatography resins, evaluating buffer strategies, and incorporating flow-through polishing help maintain productivity and robustness as processes scale.
Thermo Fisher also supports the development and manufacturing of additional therapeutic antibody modalities, including antibody-drug conjugates (ADCs) and bispecific antibodies (bsAbs). Explore these modalities within the broader bioprocessing applications framework.
For research use or further manufacturing. Not for diagnostic use or direct administration into humans or animals.